These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12629065)

  • 1. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.
    Aktas O; Waiczies S; Smorodchenko A; Dorr J; Seeger B; Prozorovski T; Sallach S; Endres M; Brocke S; Nitsch R; Zipp F
    J Exp Med; 2003 Mar; 197(6):725-33. PubMed ID: 12629065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
    Youssef S; Stüve O; Patarroyo JC; Ruiz PJ; Radosevich JL; Hur EM; Bravo M; Mitchell DJ; Sobel RA; Steinman L; Zamvil SS
    Nature; 2002 Nov; 420(6911):78-84. PubMed ID: 12422218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of atorvastatin in multiple sclerosis].
    Koh CS
    Nihon Rinsho; 2003 Aug; 61(8):1455-60. PubMed ID: 12962038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.
    Dunn SE; Youssef S; Goldstein MJ; Prod'homme T; Weber MS; Zamvil SS; Steinman L
    J Exp Med; 2006 Feb; 203(2):401-12. PubMed ID: 16476765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitor Atorvastatin mediated effects depend on the activation status of target cells in PLP-EAE.
    Mix E; Ibrahim SM; Pahnke J; Glass A; Mazón-Peláez I; Lemcke S; Koczan D; Gimsa U; Bansemer S; Scheel T; Karopka T; Böttcher T; Müller J; Dazert E; Antipova V; Hoffrogge R; Wree A; Zschiesche M; Strauss U; Kundt G; Warzok R; Gierl L; Rolfs A
    J Autoimmun; 2006 Dec; 27(4):251-65. PubMed ID: 17085013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.
    Weber MS; Prod'homme T; Youssef S; Dunn SE; Steinman L; Zamvil SS
    J Neuroinflammation; 2014 Feb; 11():29. PubMed ID: 24498870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tackling multiple sclerosis.
    Wekerle H
    Nature; 2002 Nov; 420(6911):39-40. PubMed ID: 12422206
    [No Abstract]   [Full Text] [Related]  

  • 8. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy.
    Nath N; Giri S; Prasad R; Singh AK; Singh I
    J Immunol; 2004 Jan; 172(2):1273-86. PubMed ID: 14707106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.
    Stüve O; Youssef S; Weber MS; Nessler S; von Büdingen HC; Hemmer B; Prod'homme T; Sobel RA; Steinman L; Zamvil SS
    J Clin Invest; 2006 Apr; 116(4):1037-44. PubMed ID: 16543951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin interferes with activation of human CD4(+) T cells via inhibition of small guanosine triphosphatase (GTPase) activity and caspase-independent apoptosis.
    Brinkkoetter PT; Gottmann U; Schulte J; van der Woude FJ; Braun C; Yard BA
    Clin Exp Immunol; 2006 Dec; 146(3):524-32. PubMed ID: 17100774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toward a role for statins in immunomodulation.
    Mach F
    Mol Interv; 2002 Dec; 2(8):478-80. PubMed ID: 14993398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of atorvastatin in regulating the immune response leading to vascular damage in a model of Kawasaki disease.
    Blankier S; McCrindle BW; Ito S; Yeung RS
    Clin Exp Immunol; 2011 May; 164(2):193-201. PubMed ID: 21361911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis.
    Whitham RH; Bourdette DN; Hashim GA; Herndon RM; Ilg RC; Vandenbark AA; Offner H
    J Immunol; 1991 Jan; 146(1):101-7. PubMed ID: 1701788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats.
    Li WM; Liu W; Gao C; Zhou BG
    Immunol Cell Biol; 2006 Jun; 84(3):274-80. PubMed ID: 16509827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
    Liu W; Li WM; Gao C; Sun NL
    J Autoimmun; 2005 Dec; 25(4):258-63. PubMed ID: 16242301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of atorvastatin in experimental autoimmune uveitis.
    Thomas PB; Albini T; Giri RK; See RF; Evans M; Rao NA
    Br J Ophthalmol; 2005 Mar; 89(3):275-9. PubMed ID: 15722302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors decrease Fas ligand expression and cytotoxicity in activated human T lymphocytes.
    Blanco-Colio LM; Muñoz-García B; Martín-Ventura JL; Lorz C; Díaz C; Hernández G; Egido J
    Circulation; 2003 Sep; 108(12):1506-13. PubMed ID: 12952848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin enhances humoral immune responses but does not alter renal injury in experimental crescentic glomerulonephritis.
    Phoon RK; Kitching AR; Jones LK; Holdsworth SR
    Nephrology (Carlton); 2009 Oct; 14(7):650-7. PubMed ID: 19796023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
    Kohno H; Sakai T; Saito S; Okano K; Kitahara K
    Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of atorvastatin and its role on systemic cytokine network in treatment of acute experimental colitis.
    Aktunc E; Kayhan B; Arasli M; Gun BD; Barut F
    Immunopharmacol Immunotoxicol; 2011 Dec; 33(4):667-75. PubMed ID: 21428710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.